Navigation Links
Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
Date:2/10/2012

LONDON, February 10, 2012 /PRNewswire/ --

-- Tony Sedgwick steps up to Chief Executive Officer from Chief Business Officer --

-- Thomas Christély resigns as a Director of the Company --

Silence Therapeutics plc (AIM: SLN) ("Silence" or "the Company"), a leading RNA interference (RNAi) therapeutics company, announces today the promotion of Tony Sedgwick PhD, FRCPath to the role of Chief Executive Officer from Chief Business Officer with immediate effect and the departure of Thomas Christély who has resigned as a Director of the Company for personal reasons but will ensure a smooth transition.

Dr Anthony David Sedgwick (aged 56) joined Silence in September 2011 to lead a new business development team and has been instrumental since then in helping shape the Company's future strategy and in discussions with partners, investors and other stakeholders.  Tony has extensive experience from European life science companies including more than fifteen years at Roche.  Prior to joining Silence, Tony was CEO of Novacta and Chairman of the Norwegian biotech company Plastid AS.  He was also previously CEO of two successfully acquired companies, Daniolabs Ltd. and Cambridge Biotechnology Ltd.

Commenting on the announcement Jerry Randall, Chairman of Silence Therapeutics, said: "Tony has a great deal of relevant experience gained from the global pharmaceutical industry.  He has made a very positive impact on Silence since joining in September last year and has demonstrated the right leadership skills needed as the Company continues to gain momentum. On behalf of the Board I would like to thank
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Additional Listing
2. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
3. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
4. Silence Therapeutics Provides Corporate and Development Update
5. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
6. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
7. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
8. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
9. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
10. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
11. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 ... the addition of the "Spectroscopy Equipment ... report to their offering. ... for Spectroscopy Equipment and Accessories in US$ ... Spectroscopy (UV-Vis spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, ...
(Date:8/19/2014)... 19, 2014   Synthetic Biologics, Inc. ... anti-infective biologic and drug programs targeting specific pathogens ... that its novel C. difficile development ... Interscience Conference on Antimicrobial Agents and Chemotherapy ... Synthetic Biologics, Senior Vice ...
(Date:8/18/2014)... 2014 Deep Research Report on Global ... in-depth research report on the China Linalool market. ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... environment & economic situation analysis. The report on ...
(Date:8/18/2014)... , Aug. 18, 2014 ... of advanced consumer medical devices said that ... was interviewed by CEOLIVE.TV as part of ... entire interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... Kotak explains to investors the unique advantages ...
Breaking Biology Technology:Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3
... WALTHAM, Mass. , June 2 Repligen Corporation (Nasdaq: RGEN ... quarter and fiscal year 2010, on Wednesday, June 9th, 2010 , before ... Herlihy , Ph.D., will host a conference call and webcast on the same ... provide a quarterly update on the Company. , ...
... June 2 Vermillion, Inc. (Pink Sheets: VRML), ... Patent Office has issued a Decision to Grant patent ... Cancer" to the Company. The patent claims are directed ... ovarian cancer and to the measurement of the biomarkers ...
... ... The iuvo™ Chemotaxis Assay ( http://www.bellbrooklabs.com/iuvo_chemotaxis_assay_plate.html ) Plate ... measurements of neutrophil chemotaxis ( http://www.bellbrooklabs.com/iuvo_chemotaxis_assay_plate.html ) in a ... time period of the assay. Designed for use ...
Cached Biology Technology:Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 3Vermillion Announces Issuance of European Patent 2Vermillion Announces Issuance of European Patent 3BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient 2BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient 3BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient 4
(Date:8/20/2014)... Carolina State University researchers have developed methods for electronically ... the electrical signals moths use to control those muscles. ... remotely-controlled moths, or "biobots," for use in emergency response. ... whether we can control the movement of moths for ... says Dr. Alper Bozkurt, an assistant professor of electrical ...
(Date:8/19/2014)... be made to decrease China,s increasing caesarean section rate, ... BJOG: An International Journal of Obstetrics and Gynaecology ... caesarean delivery rates in the world. Of 16 million ... Although the exact rate is not known, the current ... total caesarean rates ranging from 36% to 58%. However, ...
(Date:8/19/2014)... Long-Term Ecological Research and Network-Level Science, , Imagine if ... range of ecosystems was responding to global changes in ... if it coupled multiple decades of information about ecological ... models from dozens of different ecosystem types. , ... Ecological Research (LTER) Network, which will soon celebrate its ...
Breaking Biology News(10 mins):Research paves way for development of cyborg moth 'biobots' 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3This week from AGU: Long-term ecological research, predicting cholera outbreaks 2
... Not all trans fats are created equal and it,s time ... reflect this, particularly when it comes to dairy and beef ... the latest edition of Advances in Nutrition , natural ... beef cattle are not detrimental to health and in fact ...
... team of leading marine scientists from around the world ... the deep sea, the Earth,s largest ecosystem. Instead, ... consumers., In a comprehensive analysis published online this week ... fisheries biologists, economists, mathematicians and international policy experts show ...
... fared better than other non-advanced technology exports during the recent ... Foundation (NSF). NSF,s National Center for Science and Engineering ... 2008 to $245 billion in 2009. But this 9 ... ATP exports. ATP exports embody new or leading edge ...
Cached Biology News:Time to reboot thinking on trans fats -- natural trans fats from dairy and beef are good 2Deep-sea fish in deep trouble 2Deep-sea fish in deep trouble 3Recent trends show recession's effect on US advanced technology exports 2
... produced by a patented microwave process which ... consistent, even cell attachment, increased cell growth ... growth uunder difficult conditions, including reduced serum ... a more ecominic alternative to expensive and ...
...
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
... Lines ,High Quality, Functionally-Validated, Ion Channel Cell ... for having a critical role in nerve ... key function in pain, CNS and the ... been investigated in therapeutic areas, such as ...
Biology Products: